“RESOLVED, that the stockholders of MFA Financial, Inc. approve, on an advisory basis, the compensation of MFA’s Named Executive Officers as disclosed in the Proxy Statement for the 2020 Annual Meeting, including the Compensation Discussion and Analysis, Summary Compensation Table and other related tables and disclosures.”
This proposal, commonly known as a Say-on-Pay proposal, gives our stockholders the opportunity to express their views on the compensation of our Named Executive Officers. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our Named Executive Officers and the principles, policies and practices described in this Proxy Statement. As this is an advisory vote, the result will not be binding on the Company, the Board or the Compensation Committee, although the Compensation Committee will consider the outcome of the vote when evaluating our compensation principles, program design and practices.
You are encouraged to consider the description of the Compensation Committee’s executive compensation philosophy and its decisions in the “Compensation Discussion and Analysis” section of this Proxy Statement.
THE BOARD RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE ADVISORY (NON-BINDING) RESOLUTION TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DISCLOSED IN THIS PROXY STATEMENT.
4. APPROVAL OF THE MFA FINANCIAL, INC. EQUITY COMPENSATION PLAN, AS AMENDED AND RESTATED
We currently maintain the Existing Plan, which was originally effective as of May 20, 2010, and most recently amended and restated, effective May 21, 2015. In April 2020, the Board adopted, subject to stockholder approval, the Amended Plan, which is an amendment and restatement of the Existing Plan.
Principal Changes
Stockholder approval of the Amended Plan is being sought in order to (1) authorize additional shares, (2) meet New York Stock Exchange listing requirements, (3) allow for incentive stock options to meet the requirements of the Internal Revenue Code of 1986, as amended (the “Code”), and (4) extend the term of the Existing Plan. If our stockholders do not approve the Amended Plan, the Existing Plan will remain in effect according to its terms.
The principal changes made by the Amended Plan are to:
1.
Increase the number of shares of our Company common stock (“Common Stock”) reserved for issuance, so that the number of shares reserved for issuance under the Amended Plan, on or after June 10, 2020 (the “Effective Date”), is 18,000,000, which is equal to the sum of (i) the number of shares subject to outstanding grants under the Existing Plan as of March 27, 2020, assuming target performance of performance-based grants (3,149,758 shares), (ii) 1,972,259 shares remaining available for grant under the Existing Plan (assuming target performance of performance-based grants) and (iii) 12,877,983 additional shares of Common Stock to be made available for grants, subject to adjustments as described in the Amended Plan. Accordingly, the increase represents an additional 12,877,983 shares over the number of shares currently available for grants under the Existing Plan.
2.
Revise the grant limits under the Amended Plan, including:
•
To increase the aggregate maximum number of shares of Common Stock that may be subject to grants of stock options and stock appreciation rights made to any employee under the Amended Plan during any calendar year to 2,000,000 shares, subject to adjustments as described in the Amended Plan;
•
To provide that the aggregate maximum number of shares of Common Stock that may be subject to grants of restricted stock, phantom shares and other equity-based grants (other than stock options and stock appreciation rights) made to any employee under